iPSC-Derived Platelet Generation via GATA-1 Knockdown
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current platelet transfusions are limited by short storage half-life, variability in quality and quantity, high risk of bacterial contamination, and development of alloantibodies in multi-transfused patients, necessitating new strategies for generating platelets for infusion therapy.
Innovation Solution
The method involves generating megakaryocytes from stem cells, such as human embryonic stem cells or induced pluripotent stem cells, by decreasing GATA-1 expression, culturing them with thrombopoietin, and differentiating them into megakaryocytes, which then release clinically relevant numbers of functional platelets, either in vitro or in vivo, allowing for targeted delivery of therapeutic proteins.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If platelets are stored at room temperature for transfusion, then platelets can be used in diverse clinical settings, but bacterial contamination risk increases and storage half-life is limited
Solution Approach 1:
The patent creates a cellular copy system where patient-specific induced pluripotent stem cells (iPSCs) are generated from blood samples, then differentiated into megakaryocytes and platelets. This copying approach allows unlimited production of patient-matched platelets without relying on donor platelets that require room temperature storage and have short half-lives. The copied platelets can be stored at lower temperatures and have extended viability.
Solution Approach 2:
The patent changes the storage parameters by transitioning from room temperature storage (required for donor platelets) to controlled temperature storage of stem cell-based platelet products. This parameter change enables extended storage half-life while maintaining platelet functionality and reducing bacterial contamination risk through controlled storage conditions.
2Speed
If donor-derived platelets are used for transfusion, then immediate platelet replacement is achieved, but variability in quality and quantity occurs
Solution Approach 1:
The patent implements a self-service system where a patient's own blood sample is used to generate iPSCs, which are then differentiated into platelets. This self-service approach eliminates dependence on donor platelet availability and quality, ensuring consistent platelet production tailored to each patient's specific needs while maintaining rapid platelet replacement capability.
Solution Approach 2:
By creating a cellular copy of the patient's hematopoietic system through iPSC derivation, the patent achieves precise control over platelet quality and quantity. The copied cellular architecture ensures uniform platelet characteristics that can be consistently produced, eliminating the variability inherent in donor-derived platelets.
3Productivity
If multiple donor platelet transfusions are administered, then thrombocytopenia is treated, but alloantibody development occurs
Solution Approach 1:
The patent employs a self-service approach where each patient receives platelets derived from their own iPSCs. This eliminates the need for multiple different donor platelet transfusions that would otherwise be required to treat persistent thrombocytopenia, thereby preventing alloantibody development while maintaining treatment efficacy.
Solution Approach 2:
The patent creates a personalized copy of the patient's blood cell system through iPSC technology. By using the patient's own genetic material to generate matched platelets, the system eliminates foreign antigen exposure that would trigger alloimmunization, while still providing effective thrombocytopenia treatment through the copied functional platelets.
4Quantity of substance
If apheresis platelet collection is performed, then platelets can be obtained from donors, but a 2-hour procedure is required
Solution Approach 1:
The patent replaces the time-consuming apheresis collection process with a cellular copying approach. Patient blood samples are used to generate iPSCs, which are then differentiated into platelets in the laboratory. This copying method eliminates the need for lengthy apheresis procedures while producing sufficient platelet quantities for treatment.
Solution Approach 2:
The patent performs preliminary actions by generating iPSCs and expanding them in the laboratory before platelet differentiation and transfusion. This preliminary cell generation and expansion process eliminates the need for time-consuming donor apheresis procedures, as the platelet-producing cells are prepared in advance through controlled laboratory culture.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach achieves clinically relevant platelet levels with normal functionality and longer half-life, reducing the risk of contamination and alloimmunization, and enabling targeted therapeutic delivery, thereby addressing the limitations of traditional platelet transfusions.
Implementation Method 1
megakaryocytes release large cytoplasmic fragments into the vasculature, which must then undergo reorganization into platelets
Implementation Method 2
culturing the GATA-1 knockout or knockdown stem cells, optionally with stromal cells, in the presence of thrombopoietin, thereby generating a self-replicating, megakaryocyte-erythroid progenitor (MEP) cell
Data Source
AI summary
Compositions and methods for generating platelets and methods of use thereof are disclosed.